FY2025 Earnings Estimate for Nkarta Issued By William Blair

Nkarta, Inc. (NASDAQ:NKTX) – Investment analysts at William Blair lifted their FY2025 earnings per share estimates for Nkarta in a research note issued to investors on Tuesday, November 11th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.38). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s FY2026 earnings at ($1.29) EPS.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research note on Friday, October 31st. Needham & Company LLC restated a “buy” rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Finally, Stifel Nicolaus dropped their price target on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

Nkarta Stock Down 2.5%

NASDAQ NKTX opened at $1.96 on Thursday. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.01. Nkarta has a 12-month low of $1.31 and a 12-month high of $3.18. The firm has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86.

Institutional Investors Weigh In On Nkarta

Institutional investors and hedge funds have recently modified their holdings of the stock. Savant Capital LLC purchased a new position in shares of Nkarta during the second quarter valued at about $36,000. SG Americas Securities LLC boosted its position in Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after acquiring an additional 6,141 shares in the last quarter. CWM LLC boosted its position in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company’s stock valued at $52,000 after acquiring an additional 27,361 shares in the last quarter. Bailard Inc. purchased a new position in shares of Nkarta during the 3rd quarter worth approximately $61,000. Finally, Cerity Partners LLC bought a new position in shares of Nkarta in the 1st quarter worth approximately $55,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.